A summertime overhaul of business development structure and personnel at AstraZeneca PLC decentralizes much of the group’s activities and aligns them with specific therapeutic area strategies. Meanwhile the Big Pharma is once again in the hunt for a leader for its recently created global product and portfolio strategy (GPPS) group, as current GPPS chief and an architect of the business development (BD) revamp Marc Dunoyer transitions to group CFO.
Dunoyer’s tenure at GPPS lasted all of a few months but will nonetheless leave a mark. Alongside CEO Pascal Soriot,...